Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group LSE:RENE London Ordinary Share GB00B0DZML60 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 1.95p 1.90p 2.00p 1.95p 1.95p 1.95p 1,750,348 07:32:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -12.8 -0.4 - 61.61

Reneuron (RENE) Latest News

More Reneuron News
Reneuron Takeover Rumours

Reneuron (RENE) Share Charts

1 Year Reneuron Chart

1 Year Reneuron Chart

1 Month Reneuron Chart

1 Month Reneuron Chart

Intraday Reneuron Chart

Intraday Reneuron Chart

Reneuron (RENE) Discussions and Chat

Reneuron Forums and Chat

Date Time Title Posts
26/5/201711:31ReNeuron - a leading, clinical-stage stem cell business5,243
18/4/201714:47RP clinical trials.....11
21/6/201618:11Brexit...time to buy2

Add a New Thread

Reneuron (RENE) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Reneuron trades in real-time

Reneuron (RENE) Top Chat Posts

Reneuron Daily Update: Reneuron Group is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker RENE. The last closing price for Reneuron was 1.95p.
Reneuron Group has a 4 week average price of 1.95p and a 12 week average price of 1.95p.
The 1 year high share price is 3.63p while the 1 year low share price is currently 1.95p.
There are currently 3,159,256,868 shares in issue and the average daily traded volume is 2,659,369 shares. The market capitalisation of Reneuron Group is £61,605,508.93.
dogwalker: It's like Oppenheimer in 1942 giving a presentation at some conference in Berlin entitled 'How to build an atomic bomb 3 times more effective than the one you're trying to make at the moment'. Why would he do that ?! And why must RENE share what they're doing now with the whole world ? It's a common problem : getting your pet egg-head to know when to keep his mouth shut. They love telling everything to anyone who'll listen.All under the guise of 'being academic'; or 'spreading the word'.
dickbush: This video should hasten the day when RENE makes a public statement on the outcome of the trial. It doesn't look as though lower doses of stem cells have improved sight. So, we have to hope that the one million cell group had a better outcome. If not, the company will have to suggest yet higher doses may be needed in the next trials, always assuming they are going to continue. Today's share price decline seems to me to be entirely reasonable. There has been a suspicion for a long time that RENE would fail to achieve success with any of its trials, and this probability has just risen. I am a holder but I've always known that this was either a ten-bagger or a bust. So, I'm disappointed but not surprised. I imagine that the CEO will be fielding a few questions from major shareholders this morning, particularly Woodford.
alimo: Will never understand why prices go up and down on such small trading volume - I mean there are over 3bn shares in issue. I topped up a little today thinking there's RP news due in first half of this year, maybe MH will want to speak about it in Edinburgh next week. Someone is holding this back, though how they do it when Woodford , Toscafund, and Aviva are aboard and positive about it, beats me. Also Olaf H the CEO spent £10,000 adding 346,644 shares on 14th Dec 2016 to make his total 669,422, and even Michael H who's speaking on Wednesday, bought another 250,000 this week taking him to a total of 2,008,471. These two both have big share options exercisable subject to the achievement of the following performance conditions: 1) When the first patient is administered with a ReNeuron cell therapy in a sixth clinical trial, one third of the options will vest. 2) When the fourth clinical trial of a ReNeuron cell therapy completes, one third of the options will vest. 3) If the Total Shareholder Return (TSR) of the Company meets or exceeds that of the FTSE AIM Healthcare Index in any given three year period from the date of grant, one third of the options will vest. The vesting criteria for the TSR-related performance condition above will also apply on a proportionate basis to TSR-related performance conditions attaching to prior share option grants under the LTIP. Well, perhaps someone here understands what the above means and what the share price will have to be at before they get the big bucks. Olaf H's options pot amounts to 33m+ shares, and Michael H's pot is 29m+. In the meantime they get big salaries while our shares languish in sweeties land. We already have come a long long way and are nearer, and getting nearer every day, to the good news outcomes the company was floated for at 25p back in Aug 2005 and reaching 46p in Jan 2007. Investors in those days must must have had a real long term vision for RENE. Hopefully our CEO and CFO have the same vision to turn our company share price back up to these dizzy levels, without selling us out to be gobbled up by the AZNs of this world, before adequate payback for the 20 years of loyalty.
alimo: Rigged? I lost out big time on Renovo when the IP was lauded by many in the bio world and Phase 1&2 trials appeared to meet acceptable endpoints. Phase III trials did and then didn't(most confusing) and everything that was so promising and the glowing lost pipeline just disappeared mysteriously and wasn't worth buttons, after the tens of millions spent on development, and nobody was sent to jail! So what is being rigged, here, and for what purpose. We have been told and have watched the video results of one of the people who has greatly improved mobility during the trials. Huge amounts of money have been invested. Are you saying that original investors who have not averaged down as the huge dilution has occurred, will never see a return on their investment? Or are you saying that the share price is being manipulated to help the wealthy get wealthier. OR will it be the big sickener, that just as all the research proves successful, and the future should be rosy (even for the original investors), the company is taken/bought out, and PIs denied any opportunity to increase their wealth. If AIM is such a fiddle, why is the small investor encouraged by brokers to invest, and why don't the company regulators do more to protect small shareholders from ruthless greed of the very wealthy?
dickbush: Thanks for the link, ohisay. I have no argument with the article. This is an out-and-out speculation on my part. If it's successful it will go to many times the current share price. If it isn't successful it will go to zero. Eyes down looking for the results of Phase 2.
fredd1eboy: ReNeuron ready to rally Share 14:45 28 Oct 2016 The ‘King of Charts’ Zak Mir reckons ReNeuron Group Plc’s (LON:RENE) shares are set for a rally in the coming weeks after drifting lower over the past year or so. In the latest segment of the TIP TV Proactive Bulletin Board series, Mir says that the fundamentals for the firm seem to be solid, and he expects the share price to benefit as a result. “[There’s] an early bird opportunity here,” the technical analyst claims. “[The chart shows] some bullish divergence there so that does suggest that [shares could] rally over the next few weeks.”
city chappy: ReNeuron gets Woodford's backing as it raises £68mln 12:56 10 Jul 2015 Olav Hellebø, Renueron’s chief executive, said it is the largest funding by a cell therapy group anywhere this year. ReNeuron gets Woodford's backing as it raises £68mln Neil Woodford's interest in ReNeuron is increasing to 35.5% Star fund manager Neil Woodford has increased his stake in stem cell therapy group ReNeuron (LON:RENE) through backing a hefty fund raise at a premium to the share price. ReNeuron is raising £68.4mln of which Woodford Investment Management is putting up almost half. Woodford, one of the UK's best known money managers, was a star performer at Invesco before branching out on his own. He is a major backer of UK biotechs and the launch earlier this year of Patient Capital, a trust focused on small caps and start-ups, pulled in hundreds of millions in new money. Olav Hellebø, ReNeuron’s chief executive, said it was the largest funding by a cell therapy group anywhere this year, underlining its position in the burgeoning stem cell therapy arena. Woodford Investment Management’s stake will rise to 35.5% from 26.63% with its new shares, though has been granted a waiver from having to make a mandatory offer. Woodford paid 5p for the shares, a small premium to the closing price yesterday. The funds will be sufficient to pay for ReNeuron’s existing therapeutic programmes through to 2019 and also early development of a new exosome nanomedicine platform targeting cancer. Stem cell treatments for strokes and retinitis pigmentosa are now fully funded to the commercial stage. Hellebø said he was delighted with the amount raised through the placing. “The proceeds will enable us to rapidly exploit the potential of our CTX, hRPC and exosome nanomedicine therapeutic platforms, providing multiple opportunities to build value for our shareholders. Results from the ongoing phase II clinical trial of its stroke treatment are due in the first half of next year with phase I data for critical limb ischaemia expected around the same time. Regulatory approval was recently given for a phase I/II trial of its retinitis pigmentosa treatment with a phase II/II trial scheduled for 2017. The exosome nanomedicine platform was also generating promising early pre-clinical data, Hellebø said. There was a loss for the year to March of £8.91mln (2014: £7.07mln). Shares surged 20% to 5.86p on the news, reflecting the heavyweight backing. Michael Hunt, ReNeuron’s chief financial officer, told Proactive that a positive hit in any of the programmes going through trials would add significant value from where the company stands now. The placing would allow it to concentrate on taking its programmes through their trials and possible commercialisation without the distraction of funding worries. Shares rose 0.97p to 5.85p valuing the company at £104mln.
city chappy: Dendreon's share price soared from $0.3 billion in Feb 2009 to $7.3 billion in Apr 2010 on approval of its prostate cancer drug Provenge. Reneuron have a cancer treatment based on its exosome platform which in preclinical tests has repeatedly produced complete tumour collapse within three weeks of administration. It enters Phase 1 human trial next year. Any continued indication of success in treating cancer and Rene's shares will soar, with or without positive news from their other potentially transformational stroke and retinitis pigmentosa treatments. Rene have first mover advantage in the field of exosomes. If they target something like brain tumours, which are expensive and risky to treat surgically, they could be onto a winner. Starting to build a stake in Rene myself. The spread across three or four main areas (stroke, RP and cancer) spreads the risk and their strong cash balance means they could be self-funding until the likely target exit of a company take-over. This has the makings of a 50 bagger.
ftangftang: ReNeuron Group PLC (LON:RENE) had its stock rating reiterated as ‘Buy’ in a report released by analysts at N+1 Singer. N+1 Singer today set a target price of 10 on the company’s stock. According to the analyst this now indicates there is a potential increase of 222.58% from ReNeuron Group PLC’s current price of 3.1. LON:RENE Over the last twelve months ReNeuron Group PLC’s stock price has increased by 0% from 0.00 to 3.1 . There are currently 2,058,105,000 shares in issue with a current share value of 3.1 giving ReNeuron Group PLC a market capitalisation of 63.80M GBp . ReNeuron Group PLC (LON:RENE) has a 50 day moving average of 2.92 and a 200 day moving average of 4.41. The 52 week high for the share price is 6.5 while the 52 week low for the stock is 2.26. ReNeuron Group Plc (ReNeuron), based in the United Kingdom, is engaged in clinical-stage stem cell company. It is engaged in the research, development and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications. It develops cell-based therapies for disease conditions where the cells can be readily administered off-the-shelf to any eligible patient without the need for additional drug treatments. Its lead therapeutic candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. Its ReNcell products are used in academic and commercial sectors. Its ReN009 stem cell candidate is for the treatment of critical limb ischaemia, a side effect of diabetes. This treatment is in early-stage clinical development. Its ReN003 stem cell candidate is for the treatment of retina pigmentosa, a blindness-causing disease of the retina. This treatment is in late pre-clinical development HTTP:// cheers ft ft
rocket fuel: on admission 10 years ago the company had a mkt cap of £23.37m at a share price of 25p each. the company now has a mkt cap of £170m at a share price of 5.3p each. if on day two of admission the share price dropped to 5.3p the mkt cap would have been £4.4m today with the share price at 5.3p the mkt cap is £170m the difference between £4.4m and £170m is just a tad under 40x they floated 93.5m shares on admission and now have a grand total of 3.2bn shares and guess what? there is that 40x difference again. go figure boys n girls!
Reneuron share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170526 13:12:52